「tia」の検索結果

Recommends initiating glucocorticoid therapy in all patients with confirmed primary adrenal insufficiency (PAI). Use when PAI diagnosis is confirmed by subnormal cortisol response to ACTH stimulation test or elevated ACTH with low cortisol.

日本語の概要は準備中です。原文の説明を表示しています。

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

Guides comorbidity-stratified selection of initial and further glucose-lowering medicines for adults with type 2 diabetes using the NICE NG28 (2026) framework, covering six clinical profiles: no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, early onset, obesity, chronic kidney disease, and frailty.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends using the lowest tolerable hydrocortisone dose to potentially decrease risks of metabolic and cardiovascular disease in central adrenal insufficiency. Triggers include managing a patient with central adrenal insufficiency requiring glucocorticoid replacement.

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests initiating antihypertensive treatment while continuing fludrocortisone when blood pressure remains uncontrolled after fludrocortisone dose reduction. Trigger phrases include "BP remains uncontrolled," "persistent hypertension," or "elevated BP despite fludrocortisone adjustment."

日本語の概要は準備中です。原文の説明を表示しています。

Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests testing HPA axis functionality before and after starting GH replacement in patients not receiving glucocorticoid replacement with apparently normal pituitary-adrenal function. Triggers include initiating GH replacement in a GHD patient who is not on glucocorticoids and has normal adrenal function.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends hydrocortisone replacement dosing of 15–20 mg total daily, administered as a single dose or divided doses with the highest dose given in the morning upon awakening and the second dose in the afternoon (two-dose regimen) or second and third doses at lunch and late afternoon (three-dose regimen). Use when initiating glucocorticoid replacement for adrenal insufficiency; triggers include diagnosing adrenal insufficiency requiring glucocorticoid replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests using hydrocortisone 15–25 mg or cortisone acetate 20–35 mg daily in two or three divided oral doses for adult primary adrenal insufficiency (PAI) patients initiating glucocorticoid replacement. The highest dose is given upon awakening, with the second dose either early afternoon (≈2 h after lunch) or split into lunch and afternoon doses; consider total daily dose calculation based on chosen formulation and frequency.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends measuring serum cortisol levels at 8–9 AM as the first-line test for diagnosing central adrenal insufficiency. Use when starting diagnostic workup for suspected adrenal insufficiency; triggers include suspected adrenal insufficiency requiring initial cortisol testing.

日本語の概要は準備中です。原文の説明を表示しています。

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

Migrate test files from `as` type assertions to @total-typescript/shoehorn. Use when user mentions shoehorn, wants to replace `as` in tests, or needs partial test data.

日本語の概要は準備中です。原文の説明を表示しています。

Use when facing 2+ independent tasks that can be worked on without shared state or sequential dependencies

日本語の概要は準備中です。原文の説明を表示しています。

Azure Communication Services common utilities for Java. Use when working with CommunicationTokenCredential, user identifiers, token refresh, or shared authentication across ACS services.

日本語の概要は準備中です。原文の説明を表示しています。

Authenticate to Azure services with various credential types.

日本語の概要は準備中です。原文の説明を表示しています。

Azure Identity SDK for Python authentication. Use for DefaultAzureCredential, managed identity, service principals, and token caching.

日本語の概要は準備中です。原文の説明を表示しています。

Astropy is the core Python package for astronomy, providing essential functionality for astronomical research and data analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Core UI/UX engineering skill for building highly interactive, spatial, weightless, and glassmorphism-based web interfaces using GSAP and 3D CSS.

日本語の概要は準備中です。原文の説明を表示しています。

Design production-grade multi-agent workflows with clear pattern choice (sequential, parallel, hierarchical), handoff contracts, failure handling, and cost/context controls. Use when architecting a multi-step agent pipeline, choosing between single-agent vs multi-agent approaches, or refactoring an LLM workflow that suffers from context bloat or unreliable handoffs.

日本語の概要は準備中です。原文の説明を表示しています。

Provide comprehensive techniques for attacking Microsoft Active Directory environments. Covers reconnaissance, credential harvesting, Kerberos attacks, lateral movement, privilege escalation, and domain dominance for red team operations and penetration testing.

日本語の概要は準備中です。原文の説明を表示しています。

Ensure every factual claim in a response is backed by verifiable evidence from the codebase, documentation, or external sources. Use when preparing technical documentation, code reviews, or any output where accuracy is non-negotiable.

日本語の概要は準備中です。原文の説明を表示しています。

Keep a small requested change focused when optional refactors, architectural redesign, or unrelated cleanup threaten to expand its scope.

日本語の概要は準備中です。原文の説明を表示しています。

Start the Wasp dev server and set up full debugging visibility. This includes running the server (with access to logs), and connecting browser console access so the agent can see client-side errors. Essential for any development or debugging work.

日本語の概要は準備中です。原文の説明を表示しています。

Coordinate complex engineering work across bounded subagents while protecting the main context, preventing edit conflicts, and measuring whether delegation was worthwhile. Use when the user asks to delegate, parallelize, orchestrate, use subagents, fan out a review, or handle a large task with independent workstreams; do not use for small, tightly coupled, or inherently sequential tasks.

日本語の概要は準備中です。原文の説明を表示しています。